GMAB
Genmab A/S NASDAQ Listed Jun 1, 2009$27.04
Mkt Cap $16.7B
52w Low $18.89
49.3% of range
52w High $35.43
50d MA $27.30
200d MA $28.87
P/E (TTM)
17.1x
EV/EBITDA
17.3x
P/B
2.8x
Debt/Equity
0.9x
ROE
—
P/FCF
16.6x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$27.30
200d MA
$28.87
Avg Volume
1.6M
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Kalvebod Brygge 43 · Copenhagen, G7 1560 · DK
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | 0.46 | 0.05 | -89.1% | 30.00 | -2.5% | -2.8% | -3.7% | -2.4% | -2.4% | -2.0% | — |
| Nov 6, 2025 | AMC | 0.48 | 0.65 | +35.4% | 28.84 | -0.4% | -0.6% | +0.8% | +5.1% | +5.7% | +4.9% | — |
| Aug 7, 2025 | AMC | 0.39 | 0.54 | +38.5% | 22.69 | -5.9% | -5.6% | -7.1% | -3.6% | -0.1% | +1.3% | — |
| May 8, 2025 | AMC | 0.23 | 0.31 | +34.8% | 19.42 | +1.0% | -0.3% | +2.6% | -0.6% | -1.8% | +1.2% | — |
| Feb 12, 2025 | AMC | 0.28 | 0.57 | +103.6% | 19.69 | +2.1% | +6.2% | +8.2% | +10.6% | +11.6% | +14.0% | — |
| Nov 6, 2024 | AMC | 0.35 | 0.29 | -17.1% | 22.33 | +1.4% | +3.5% | +3.4% | +3.9% | +0.6% | -3.0% | — |
| Aug 8, 2024 | AMC | 0.29 | 0.22 | -24.1% | 27.07 | -1.8% | -2.4% | -2.1% | -1.8% | -1.0% | +0.5% | — |
| May 2, 2024 | AMC | 0.16 | 0.16 | +0.0% | 27.72 | +7.3% | +7.2% | +4.7% | +5.7% | +3.9% | +3.9% | — |
| Feb 14, 2024 | AMC | 0.34 | 0.36 | +5.9% | 27.59 | +5.3% | +2.3% | +4.1% | +4.9% | +4.9% | +5.5% | — |
| Nov 7, 2023 | AMC | 3.14 | 0.47 | -85.0% | 29.52 | +7.4% | +5.0% | +5.6% | +6.5% | +8.9% | +9.7% | — |
| Aug 3, 2023 | AMC | 2.18 | 0.30 | -86.2% | 39.28 | -4.6% | -4.8% | -4.3% | -4.4% | -3.8% | -4.2% | — |
| May 10, 2023 | AMC | 0.65 | 0.05 | -92.3% | 40.35 | +4.3% | +4.0% | +3.3% | +4.4% | +3.0% | +2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.11 | $26.46 | +1.3% | +1.6% | +1.3% | +3.6% | +5.4% | +6.8% |
| Apr 22 | Goldman Sachs | Upgrade | Neutral → Buy | — | $27.06 | $28.05 | +3.7% | +2.3% | -0.3% | -0.7% | -1.6% | -1.0% |
| Feb 23 | Guggenheim | Maintains | Buy → Buy | — | $29.29 | $28.43 | -2.9% | -0.1% | +0.4% | +0.0% | -0.2% | +0.5% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.00 | $29.25 | -2.5% | -2.8% | -3.7% | -2.4% | -2.4% | -2.0% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.40 | $33.02 | -4.0% | -4.3% | -3.1% | -5.1% | -3.3% | -4.0% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.25 | $31.38 | -2.7% | -2.9% | +2.2% | +2.6% | +5.1% | +3.8% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.66 | $29.36 | +2.4% | +1.4% | +5.8% | +6.3% | +5.5% | +5.6% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $28.84 | $28.73 | -0.4% | -0.6% | +0.8% | +5.1% | +5.7% | +4.9% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.75 | $32.53 | -0.7% | -0.1% | +0.0% | +1.3% | -6.7% | -8.0% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.77 | $32.00 | +0.7% | +1.1% | +5.6% | +4.8% | +2.7% | +3.1% |
| Sep 24 | Guggenheim | Upgrade | Neutral → Buy | — | $28.73 | $28.98 | +0.9% | +2.5% | +0.4% | +1.2% | +2.1% | +6.8% |
| Sep 23 | Guggenheim | Upgrade | Neutral → Buy | — | $28.60 | $28.70 | +0.3% | +0.5% | +3.0% | +0.8% | +1.6% | +2.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.98 | $23.36 | +1.7% | +1.4% | +1.9% | +3.7% | +4.7% | +6.3% |
| Jul 8 | Truist | Maintains | Buy → Buy | — | $20.52 | $20.84 | +1.6% | +3.6% | +5.2% | +6.5% | +4.3% | +4.6% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.93 | $19.52 | -2.1% | -3.1% | -4.3% | -1.4% | -0.3% | +1.3% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.98 | $17.71 | -1.5% | +4.7% | +0.2% | +4.6% | +7.5% | +8.5% |
| Mar 11 | William Blair | Upgrade | Market Perform → Outperform | — | $21.98 | $20.71 | -5.8% | -7.8% | -8.1% | -9.2% | -6.7% | -5.4% |
| Mar 11 | Truist | Maintains | Buy → Buy | — | $21.98 | $20.71 | -5.8% | -7.8% | -8.1% | -9.2% | -6.7% | -5.4% |
| Feb 13 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $19.69 | $20.11 | +2.1% | +6.2% | +8.2% | +10.6% | +11.6% | +14.0% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.97 | $21.26 | +1.4% | +1.5% | +0.8% | -0.8% | -6.6% | -5.3% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.80 | $21.52 | -1.3% | -3.8% | -2.3% | -3.1% | -4.6% | -10.2% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.18 | $22.15 | -0.1% | +0.0% | -0.1% | -2.1% | -2.4% | -8.8% |
| Nov 8 | BMO Capital | Maintains | Outperform → Outperform | — | $23.11 | $22.85 | -1.1% | -0.1% | +0.4% | -2.8% | -6.3% | -8.4% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.18 | $22.83 | -1.5% | -2.5% | -0.9% | -0.9% | -1.7% | -1.8% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.48 | $25.92 | -2.1% | -3.6% | -8.8% | -9.3% | -10.0% | -8.9% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.90 | $26.75 | -0.6% | -1.2% | -1.7% | -2.6% | -1.6% | -5.1% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.49 | $26.55 | +0.2% | +1.5% | +0.3% | -0.2% | -1.1% | -0.0% |
| Sep 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $27.50 | $27.15 | -1.3% | -2.1% | -3.7% | -2.2% | -3.3% | -3.9% |
| Sep 9 | Truist | Maintains | Buy → Buy | — | $27.52 | $27.39 | -0.5% | -0.2% | -0.1% | -2.1% | -3.7% | -2.3% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.36 | $27.79 | +1.6% | +1.9% | +1.2% | +1.6% | +1.6% | +0.2% |
| Aug 20 | JP Morgan | Downgrade | Overweight → Neutral | — | $27.75 | $26.81 | -3.4% | -2.0% | -0.9% | -2.6% | -1.5% | -1.4% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.75 | $26.81 | -3.4% | -2.0% | -0.9% | -2.6% | -1.5% | -1.4% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.07 | $26.59 | -1.8% | -2.4% | -2.1% | -1.8% | -1.0% | +0.5% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.07 | $26.38 | +1.2% | +1.5% | +1.5% | +3.8% | +1.4% | +1.7% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.29 | $28.33 | +0.1% | +0.2% | -0.2% | -7.8% | -6.4% | -6.5% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.83 | $27.19 | +1.3% | +1.5% | +3.4% | +3.6% | +4.1% | +3.9% |
| Jul 15 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $27.05 | $26.53 | -1.9% | -1.9% | -0.2% | -0.8% | +0.7% | +2.6% |
| Jun 27 | BTIG | Maintains | Buy → Buy | — | $25.67 | $25.72 | +0.2% | -0.4% | -2.1% | -3.2% | -3.0% | -2.0% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.67 | $25.72 | +0.2% | -0.4% | -2.1% | -3.2% | -3.0% | -2.0% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.80 | $25.69 | -0.4% | +0.3% | +0.9% | +0.1% | -0.1% | -0.5% |
| Jun 4 | Truist | Maintains | Buy → Buy | — | $28.83 | $28.46 | -1.3% | -1.1% | -0.3% | -1.0% | -3.7% | -3.2% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.20 | $28.44 | +0.9% | +2.2% | +1.1% | +1.9% | +1.2% | -1.5% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.98 | $29.83 | -0.5% | -1.0% | -2.8% | -0.6% | -2.1% | -6.6% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.72 | $29.73 | +7.3% | +7.2% | +4.7% | +5.7% | +3.9% | +3.9% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.57 | $27.94 | -2.2% | -3.1% | +0.6% | -3.0% | +4.0% | +1.6% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.30 | $30.32 | +3.5% | +1.2% | +1.6% | +1.9% | +2.3% | +2.2% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.83 | $30.50 | -1.1% | -0.6% | -3.0% | -1.8% | -2.8% | -5.0% |
| Mar 26 | Truist | Maintains | Buy → Buy | — | $29.98 | $30.92 | +3.1% | +2.8% | +2.2% | -0.2% | +1.0% | -0.1% |
| Mar 26 | Morgan Stanley | Maintains | Underweight → Underweight | — | $29.98 | $30.92 | +3.1% | +2.8% | +2.2% | -0.2% | +1.0% | -0.1% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.75 | $28.92 | +0.6% | +0.4% | +2.3% | +5.4% | +10.2% | +9.3% |
No insider trades available.
No recent filings available.
Data updated apr 26, 2026 10:42am
· Source: massive.com